These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 16146671)

  • 1. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Takeuchi M
    Med Hypotheses; 2006; 66(2):273-5. PubMed ID: 16216433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
    Kume S; Kato S; Yamagishi S; Inagaki Y; Ueda S; Arima N; Okawa T; Kojiro M; Nagata K
    J Bone Miner Res; 2005 Sep; 20(9):1647-58. PubMed ID: 16059636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H
    Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus a risk for osteoporosis?
    Leidig-Bruckner G; Ziegler R
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S493-514. PubMed ID: 11460594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Aug; 71(2):259-61. PubMed ID: 18448262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Dec; 71(6):876-8. PubMed ID: 18783891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis.
    Ji JD; Woo JH; Choi SJ; Lee YH; Song GG
    Med Hypotheses; 2009 Aug; 73(2):201-2. PubMed ID: 19349124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
    Rojas A; Morales MA
    Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
    Friedman EA
    Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.